NEW DELHI: Pharmaceutical company Abbott announced on Tuesday that it has launched a medical device in India that can be implanted in premature babies and newborns with congenital heart defects.
The company launched Amplatzer Piccolo Occluder in India.
This medical device can be implanted in the smallest babies (weighing as little as 700 grams) using a minimally invasive procedure to treat conditions such as Patent Ductus Arteriosus (PDA).
The device, which is even smaller than a pea, now offers hope for premature and newborn babies who need corrective treatment, who may not respond to medications, and are at high risk to undergo corrective surgery, Abbott said in a statement.
One of the most common congenital heart defects in premature babies, PDA is a potentially fatal opening between two blood vessels leading from the heart.
“Piccolo represents a critical advance in the quality of care for the most vulnerable premature babies who may not be able to undergo surgery to repair their hearts,” said Abbott’s Structural Heart business general manager. in India and the Payal Agrawal subcontinent.
About 3.5 million premature babies are born in India every year.
The incidence of PDA ranges from 15 to 37 percent in newborns weighing less than 1750 grams.
Amplatzer Piccolo Occluder is a self-expanding wire mesh device that is inserted through a small incision in the leg and guided through the vessels to the heart, where it is placed to seal the opening in the heart.
It is designed to allow the physician to insert it into the aortic or pulmonary artery as well as to recover and redeploy the device for optimal placement.